<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820326</url>
  </required_header>
  <id_info>
    <org_study_id>I03002</org_study_id>
    <nct_id>NCT00820326</nct_id>
  </id_info>
  <brief_title>Efficacy of Dolasetron in Patients With Fibromyalgia</brief_title>
  <acronym>Dolastron</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy of DOLASETRON in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study offers a new treatment, dolasetron or ANZEMET ®, which will be administered by
      intravenous way once a day during a 4 days Hospitalization.

      This study is double blind (neither you nor the physician will know if you are receiving
      active study drug or placebo).

      Randomisation at the beginning of the study will decide whether you receive active treatment
      or its placebo.

      This treatment will be renewed after one month, after 2 months and after 3 months.

      If the study staff determines that you are eligible and you decide to participate, there will
      be approximately 6 study visits in about 9 months. During these visits, you will undergo
      routine health exams and complete different kinds of questionnaires.

      Following this first period of 3 months, you agree to come back for consultation at month 4,
      month 6 and month 12 for monitoring and evaluating the effects of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Improving visual analogue scale (VAS) between Inclusion visit and month 3</measure>
    <time_frame>Inclusion visit and month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improving visual analogue scale (VAS)</measure>
    <time_frame>Between Inclusion visit, month 1, month 2, month 4, month 6, and month 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia impact questionnaire SF-36 scale and Beck depression scale</measure>
    <time_frame>Between Inclusion visit, month 1, month 2, month 4, month 6, and month 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety index</measure>
    <time_frame>Between Inclusion visit, month 1, month 2, month 4, month 6, and month 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of painful trigger points</measure>
    <time_frame>Between Inclusion visit, month 1, month 2, month 4, month 6, and month 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Dolasetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolasetron</intervention_name>
    <description>Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3</description>
    <arm_group_label>Dolasetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 75

          -  Primitive Fibromyalgia according to ACR criteria

          -  Patient no responding to conventional treatment

          -  Women of childbearing age using an efficace contraception

          -  Signed consent

        Exclusion Criteria:

          -  Inflammatory rheumatic diseases

          -  Diseases of the system: Gougerot Sjögren, polymyositis, vasculitis,

          -  Infectious diseases: hepatitis B and C, lyme disease, HIV,

          -  Hypothyroidism,

          -  Bone and mineral metabolism disorders

          -  Disorders of cardiac conduction

          -  Failure of Heart, of kidney or liver,

          -  Patient allergic to dolasetron

          -  Pregnant or nursing women

          -  Women without means of contraception,

          -  Age &lt;18 or &gt; 75 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2008</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>January 9, 2009</last_update_submitted>
  <last_update_submitted_qc>January 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marie SENGELEN</name_title>
    <organization>CHU de Limoges</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolasetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

